What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.

Four doses of Eli Lilly's diabetes drug Mounjaro would remain in tight supply through 2024 due to soaring demand, the U.S. Food and Drug Administration's website showed.

Citi analyst Andrew Baum raised his price target on Lilly stock to $895 from $675, citing increased sales expectations for a new drug.

The pharmaceutical and e-commerce industries have proven to be resilient places to invest. Eli Lilly is riding a wave of sales from new blockbuster drugs on top of its flagship products.

Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as...

Eli Lilly's stock price rise continues unabated in 2023, backed by strong topline growth in 2023 and a sunny outlook for 2024. Its diabetes treatments look particularly encouraging, with Mounjaro's...

The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes co...

Kevin Mahn, Hennion & Walsh Asset Management president and CIO, joins 'Squawk Box' to discuss the latest market trends, why he believes AI isn't the only game in town for the markets, and more.

The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the dom...

In the most recent trading session, Eli Lilly (LLY) closed at $774.90, indicating a +0.23% shift from the previous trading day.

Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the...

Demand for obesity and diabetes treatments such as Ozempic, Mounjaro, and Wegovy is off the charts. Novo Nordisk and Eli Lilly manufacture the primary medications used to treat obesity care and dia...

Some patients are willing to pay more for GLP-1 weight loss drugs like Wegovy than others — and it's strongly correlated to their annual income.

Eli Lilly's stock price has increased by 129% in a year, with a Forward Price-To-Earnings Ratio of 60.4. Lilly's valuation in a base case scenario at $171/share, considering traditional drug revenu...

Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appet...